Introduction
Numerous studies have tested for associations between polymorphisms in the gene encoding for methylenetetrahydrofolate reductase (MTHFR) and major psychiatric disorders including schizophrenia (SZ), bipolar disorder (BPD) and unipolar depressive disorder (UDD). These studies have yielded largely inconclusive and often mixed results (Betcheva et al., 2009; Feng et al., 2009; Gaysina et al., 2008; Gilbody et al., 2007; Pan et al., 2009; Yu et al., 2004; Yuan et al., 2008) . MTHFR is a crucial enzyme involved in one-carbon metabolism (OCM), a folate-mediated pathway essential for purine and thymidylate biosynthesis, the methylation of DNA and amino acids, and is necessary for reactions forming neurotransmitters (Sugden, 2006) . MTHFR and OCM play key roles in physiologic processes by regulating the channeling of onecarbon units between the DNA cycle (nucleotide synthesis) and the methylation cycle (Frankenburg, 2007; Krebs et al., 2009; Laanpere et al., 2010) . Dysfunction of the OCM cycle has been linked to neural tube defects (van der Put et al., 2001; Zhang et al., 2008) and autism (Pasca et al., 2009) , and may contribute to the pathogenesis of other disorders, including leukemia (de Jonge et al., 2009; Wiemels et al., 2001) , dementia (Kim et al., 2008; Kronenberg et al., 2009) , colorectal cancer (Kim, 1999; Levine et al., 2010) , cardiovascular disease (Smulders and Stehouwer, 2005) and congenital abnormalities (Carmichael et al., 2009; Wani et al., 2008) . Given MTHFR's essential role in brain function and neurodevelopment (del Rio Garcia et al., 2009; Ueland et al., 2001) , and that family and twin studies have demonstrated considerable shared genetic variance between psychiatric disorders (Cardno et al., 2002; Lichtenstein et al., 2009; McGuffin et al., 2003; Van Snellenberg and de Candia, 2009) , it is reasonable to hypothesize that genetic variation in MTHFR may contribute to the shared genetic vulnerability of common psychiatric disorders. In addition to this genetic contribution, environmental factors also contribute to the development of psychiatric disorders (Lahiri et al., 2009) . It has been proposed that epigenetic mechanisms such as DNA methylation play important roles in biological mediation of environmental influences and underlie gene-environment interplay in the aetiology of mental disorders (Bredy et al., 2010; Iwamoto and Kato, 2009; Narayan and Dragunow, 2010) . Thus variation in OCM may potentially moderate environmental influences affecting gene expression.
MTHFR is located on chromosome 1p36.3 (Frosst et al., 1995; van der Put et al., 1998) . Despite this gene's potential importance, research focusing on the role of MTHFR in psychiatric disorders has focused almost exclusively on two common polymorphisms: (1) a CT transition at nucleotide 677 and (2) an AC transition at nucleotide 1298 (Frosst et al., 1995; Laanpere et al., 2010; van der Put et al., 1998) . C677T is located in exon 4 and results in a transition from an alanine into a valine amino acid (Ala222Val) in the catalytic domain, with each copy of the 677T allele causing a 35% reduction of enzyme activity (Frosst et al., 1995) . A1298C is located in exon 7 and changes glutamate into an alanine amino acid (Glu429Ala). This results in enhanced binding of inhibiting enzymes, with each copy of the 1298C allele decreasing enzyme activity (van der Put et al., 1998) . Some earlier studies have indicated that demographic differences influence the effect of genetic variations of MTHFR on major psychiatric disorders. For example, Sazci et al. (2005) and Zintzaras (2006) reported that ethnicity and sex may influence the association between MTHFR variants and psychiatric disorders.
We designed this study to clarify if MTHFR C677T and/or MTHFR A1298C show significant associations with SZ, BPD and UDD, both as group of major psychiatric disorders or in isolation. In these analyses, we accounted for the potential modifying effects of ethnicity, year of publication and sex.
Material and methods

Identification and selection of studies
All non-familial, cross-sectional, and case-control studies examining the association between genetic variations of MTHFR and psychiatric disorders published before March 01, 2010 were included. The articles were identified by computer-based searches of the following databases: MEDLINE, EMBASE, PsycINFO, Pubmed, Web of Science, Science Direct, and the website of the schizophrenia research forum (SzGene; http://www.schizophreniaforum.org/ res/sczgene/default.asp, accessed on January 31st 2010). Separate searches for each diagnostic group were conducted combining the following terms: ''Methylenetetrahydrofolate reductase'', ''MTHFR'', ''polymorphisms'', ''C677T'' and ''A1298C'', in the following combinations ''Methylenetetrahydrofolate reductase'' OR ''MTHFR'' AND ''polymorphisms'' OR ''C677T'' OR ''A1298C''. Separate searches used the following disorder-specific key words: ''schizophrenia'', ''psychotic disorder'', ''psychosis'', and ''schizoaffective disorder'' were used for SZ; ''bipolar'', ''bipolar disorder '', ''bipolar illness'' and ''manic depressive disorder'' for BPD, and ''depression'', ''depressive disorder'', ''major depressive disorder'', ''depressive episode'', ''major depressive episode'', ''unipolar disorder'' and ''affective disorder'' for UDD. No language restrictions were used. Figs. 1-3 summarize the information flow through the different phases of the systematic review.
Data extraction
After removing duplicate studies, two independent researchers (O.P. and L.H.) evaluated the relevance of the identified studies (determination of the distribution of the C677T and A1298C genotypes in controls and patients) by reading the abstract or, when necessary, the full article. All references cited in the studies were screened. Abstracts for conferences, case reports, editorials and review articles were furthermore screened to identify other published and unpublished work. Figs. 1-3 summarize the identification, screening, eligibility, and inclusion of the studies that were identified using the searches on SZ (Fig. 1) , BPD (Fig. 2) , and UDD (Fig. 3) .
Those studies considered ineligible for inclusion included those that: (i) examined associations between MTHFR and disorders other than the three aforementioned psychiatric disorders; (ii) reviewed past associations studies between MTHFR and psychiatric disorders and did not present new case-control comparison data; (iii) used linkage and family designs; and (iv) were meta-analyses of the association between MTHFR and psychiatric disorders.
The following information was extracted for each eligible study: authors, journal, year of publication, country of origin and ethnic group of study population, selection and characteristics of cases and controls, diagnosis and diagnostic instruments used, demographics of cases and controls, matching of controls, genotyping method, and the number of cases and controls for which C677T and/or A1298C genotyping was conducted. Genotype distributions, allele frequencies as well as genotype distributions per sex were extracted for cases and controls. When not reported in the original article, allele frequencies were calculated from the genotype distributions.
In case of overlapping samples in more than one article, we examined the most recently described sample and/or the largest sample. When different articles utilized the same control group (Arinami et al., 1997; Jonsson et al., 2008; Kempisty et al., 2007 Kempisty et al., , 2006 Kim et al., 2009b; Kunugi et al., 1998; Reif et al., 2005; Tan et al., 2004) , odds ratios (ORs) for these samples were calculated by comparing the genotypic distribution of the group with the relevant psychiatric disorder(s) with the control group.
The presence of a psychiatric disorder was defined as a diagnosis of this disorder using validated diagnostic instruments, standardized diagnostic interviews, or questionnaires (in some publications on UDD). To assess the impact of studies making use of questionnaires, the robustness of the analyses was tested with sensitivity analyses (please see detailed description in the section below). 
Statistical methods
Pooled ORs and 95% confidence intervals (CI) were calculated using five genetic models of analysis (Table 1) : model 1 is the recessive genotype model, model 2 is the dominant genotype model, model 3 and 4 are co-dominant genotype models, and model 5 is the allele frequencies model. Heterogeneity between studies was tested using the chi-squared test (cut-off: p < 0.05) and quantified using the I 2 metric (which is independent of the number of studies in the meta-analysis). The pooled OR was estimated using either the fixed effects (FE) model or the random effects (RE) model depending on the level of heterogeneity. Meta-regression was used to investigate effects of the possible modifiers of diagnosis, sex, ethnic group and year of publication. Because missing data of some of the factors would reduce the power of the analysis, the possible modifiers were tested in isolation as well as together in each of the five genetic models. The following additional tests were used for evaluation of robustness of the results. The distributions of the genotypes in the control groups were tested for Hardy-Weinberg equilibrium using the exact test. Sensitivity analyses were conducted for samples not in HardyWeinberg equilibrium (p < 0.05 in the exact test) to evaluate the impact of these studies. In a second sensitivity analysis, we excluded samples with p-values <0.1 in the exact test; this was done because the exact test for Hardy-Weinberg equilibrium may be influenced negatively by small effects and small sample sizes of the included studies (Salanti et al., 2005) .
Cumulative meta-analyses, i.e. repeated performances of metaanalyses whenever a new study was available, were conducted to evaluate the impact of the year of publication. Publication bias was investigated with funnel plot analyses, the Egger regression test for asymmetry, and Harbord's modification of the Egger's test (Sterne, 2009 ). When present, the impact of publication bias was determined with the trim and fill method.
All analyses were conducted using STATA version, 11.0, software (Stat Corp., College Station, Texas), using the commands metan, metacum. metabias, metafunnel, metatrim, and metareg.
Results
In total, 56 articles (25 studies on SZ, eleven on BPD, and 20 on UDD) were eligible for inclusion. Because three articles reported ORs for all three disorders (Arinami et al., 1997; Kunugi et al., 1998; Tan et al., 2004) and four articles reported ORs for two disorders (Jonsson et al., 2008; Kempisty et al., 2006; Kim et al., 2009b; Reif et al., 2005) , a total of 46 articles were included. The corresponding author, first author and (if necessary) other co-authors were contacted for retrieval of information not reported in the original article. The authors of four articles/abstracts could not be reached, thus their data were not used or only in part (Hickie et al., 2005; Kim et al., 2009b; Lok et al., 2008; Perez et al., 2009) . Therefore, this metaanalysis included data reported in 42 publications describing 51 samples that consisted of 29,502 subjects (9648 patients and 19,854 controls) with genotyping of MTHFR C677T, and 7934 subjects (3507 patients and 4427 controls) with genotyping of MTHFR A1298C. Table 2 summarizes, for the different studies, the name of the first author, year of publication, country, ethnic group, case/ control characteristics and MTHFR SNP genotyped.
MTHFR C677T
The meta-analysis of the association between MTHFR C677T and major psychiatric disorders (SZ, BPD and UDD combined) was conducted on a total of 36 articles describing 48 samples comprising 22 SZ samples, nine BPD samples and 17 UDD samples. Table 3 provides an overview of the included samples with MTHFR C677T genotype distribution. 
Table 1
Overview of the genetic models used in the meta-analysis for MTHFR C677T and A1298C.
Model
MTHFR C677T ORs for more than one diagnosis were reported in six articles (Arinami et al., 1997; Jonsson et al., 2008; Kempisty et al., 2006; Kunugi et al., 1998; Reif et al., 2005; Tan et al., 2004) . The presence of both a control group and a group with psychiatric disorder(s) was reported in 39 samples, with 34 samples reporting a casecontrol design and five samples using a cross-sectional design in the general population. UDD was diagnosed with questionnaires rather than with clinical interviews in these five cross-sectional general population samples (Almeida et al., 2005 (Almeida et al., , 2008 Bjelland et al., 2003; Kim et al., 2009a; Lewis et al., 2006) as well as in one case-control sample (Slopien et al., 2008) . Screening for psychiatric symptoms or disorders in control subjects was reported in 29 samples, but not in eight other samples (Arinami et Sazci et al., 2003) ; information on psychiatric screening of control subjects was not available for two samples (Yu et al., 2004) . Matching of control subjects on ethnic group, geographical area, sex and/ or age was performed in twelve samples (Almeida et al., 2005; Chen et al., 2009; Crisan, 2006; Feng et al., 2009; Gaysina et al., 2008; Hernandez Sanchez et al., 2009; Jonsson et al., 2008; Kelly et al., 2004; Roffman et al., 2008; Sazci et al., 2003 Sazci et al., , 2005 Tan et al., 2004) . Genotyping was performed using polymerase chain reaction (PCR) based methods in all studies.
Meta-analysis. Significant between-study heterogeneity was found for all genetic models (Table 4 ) and for this reason random effects were used to calculate the ORs. All statistical models showed significant statistical associations between MTHFR C677T and major psychiatric disorder (SZ, BPD and UDD combined). The highest OR was found for TT genotype carriers 52.4%). Fig. 4 shows the results from the random effects metaanalysis of the co-dominant genotype model 3 of the association between MTHFR C677T and major psychiatric disorder. Significant ORs were also found in the other genetic models and varied from 1.11 in genetic model 2 (random effects OR CCvCT/TT = 1.11, 95 % confidence interval (CI): 1.01-1.23; I 2 58.2%) to 1.24 in genetic model 1 (random effects OR CC/CTvTT = 1.24, 95 % confidence interval (CI): 1.10-1.39; I 2 39.5%; Table 4 ). Meta-regression analyses showed no significant moderation of the meta-analytic effect size by diagnosis, sex, ethnic group and year of publication (Table 5) . Sensitivity analysis. Two out of a total of 39 control samples were in Hardy-Weinberg disequilibrium (p-value < 0.05) (Mavros et al., 2008; Philibert et al., 2006) and another two in possible disequilibrium (p < 0.10) (Arinami et al., 1997; Kim et al., 2009b) (Table 3) . Exclusion of these four samples from the meta-analysis did not alter the results (Table 4) . Cumulative meta-analysis by year of publication showed that the association between major psychiatric disorders and MTHFR C677T was reduced in strength and magnitude over the years, but nevertheless remained statistically significant over the entire period (Fig. 5) .
Analysis of possible publication bias, using funnel plot analyses, Egger's test and Harbord's modification of the Egger's test, indicated publication bias when using genetic models 2 and 5 (Table  4) . Subsequent data correction using the trim and fill method led to a (borderline) non-significant p-value in genetic model 2 (p = 0.051; OR: 1.10; 95% CI 1.00-1.22), while the p-value remained significant in genetic model 5 (p = 0.002; OR: 1.12; 95% CI 1.04-1.21). No publication bias or small study effects were found in the other genetic models. Fig. 4 . Results of the random effect meta-analysis of the association between MTHFR C677T and the combined diagnostic group of major psychiatric disorders schizophrenia, bipolar disorder and unipolar depressive disorder, as tested in genetic model 3.
Table 5
Results of the meta-regression analyses of the MTHFR C677T meta-analysis for the five genetic models tested, including diagnosis, year of publication, ethnic group and sex as possible modifiers in separate (one modifier) and combined analyses (multiple modifiers). 
MTHFR A1298C
The meta-analysis of the associations between MTHFR A1298C and major psychiatric disorder (SZ, BPD and UDD combined) included 13 articles describing a total of 18 samples comprising 13 SZ samples, four BPD samples and one UDD sample (Table 6 ). Of these 13 articles, three articles reported results for two psychiatric disorders (Jonsson et al., 2008; Kempisty et al., 2007; Reif et al., 2005) and two articles included samples from more than one country (Jonsson et al., 2008; Yu et al., 2004) . All studies used a case-control design and clinical diagnoses of psychiatric disorders were made by interviews or examination of patients' records by psychiatrists. Seven articles described screening of the control group for psychiatric disorders (Betcheva et al., 2009; Crisan, 2006; Jonsson et al., 2008; Lee et al., 2006; Ozbek et al., 2008; Sazci et al., 2005; Vilella et al., 2005) and five articles reported matching of the control group (Crisan, 2006; Jonsson et al., 2008; Lee et al., 2006; Sazci et al., 2003 Sazci et al., , 2005 . All samples used a PCR-based method for genotyping the A1298C polymorphism.
Meta-analysis. Analyzing the data from the18 samples for association between MTHFR A1298C and major psychiatric disorders revealed significant ORs for each of the five genetic models. However, meta-regression analyses showed that diagnosis was a significant moderator and therefore further analyses were conducted stratified for diagnosis (Table 8) .
Schizophrenia
Ten studies reported data on the association between MTHFR A1298C and SZ (Table 6 ). Because the level of heterogeneity between studies varied, both fixed effects models and random effects models were used. Diagnosis of SZ was not significantly associated with MTHFR A1298C (Table 7 and Fig. 6 ). In addition, meta-regression analyses revealed no significant influence of sex or ethnic group. Year of publication (Table 8 ) modified the association significantly in genetic models 2, 3 and 5; later year of publication was associated with a decreased OR.
Sensitivity analyses. Hardy-Weinberg disequilibrium was observed in one study (p-value <0.01; (Lee et al., 2006) ), and seemed likely for another one (p-value = 0.07; (Jonsson et al., 2008 )) ( Table  6 ). Exclusion of the aforementioned study, as well as exclusion of both studies from the analyses did not change the results of the meta-analysis (Table 7) . Funnel plot analyses, Egger's test and Harbord's modification of Egger's test did not support presence of publication bias (Table 7) .
Bipolar disorder
Four articles reported data on the association between BPD and MTHFR A1298C (Jonsson et al., 2008; Kempisty et al., 2007; Ozbek et al., 2008; Reif et al., 2005) (Table 6 ). Because of variable study heterogeneity among the five genetic models, the random effects model was used in genetic model 3 (random effects OR AAvCC = 2.03, 95 % CI: 1.07-3.86; I 2 64.0%), while fixed effects models were used in genetic models 1, 2, 4 and 5 (Table 7 and Fig. 7 ). Diagnosis of BPD was significantly associated with MTHFR A1298C in all five genetic models (Table 7) . Meta-regression analyses revealed no significant moderation by year of publication or sex. Ethnic group could not be analyzed as a possible modifier in these analyses because all studies were conducted in White samples (Table 8) . Sensitivity analyses. Hardy-Weinberg disequilibrium was observed in one study (p = 0.02; (Reif et al., 2005) ), (Table 6 ) and sensitivity analyses indicated that exclusion of this study (Reif et al., 2005) led to a loss of statistical association with mental disorders in genetic models 1, 3 and 4 but not in genetic models 2 and 5 ( Table 7) . Analysis of funnel plots, Egger's test and Harbord's modification to Egger's test indicated no evidence for publication bias.
Depression
The study conducted by Reif et al. (2005) was the only study that examined the association between MTHFR A1298C and UDD (Reif et al., 2005) (Table 6 ). Their data indicated that the diagnosis of UDD was significantly associated with MTHFR A1298C in genetic model 1 (fixed-effect OR AA/ACvCC = 2.63, 95 % CI: 1.02-6.77; I 2 0%)
but not in the other genetic models (Table 7) .
Discussion
Main findings
The present meta-analysis examining MTHFR C677T in 9648 patient and 19,854 control subjects indicated that carriers of the 
Table 7
Odd ratio's (ORs) and confidence intervals (CI) of the 5 genetic models tested in the meta-analysis of MTHFR A1298C and the risk of major psychiatric disorders, a including both fixed and random effects models, testing for heterogeneity with the I 2 test, publication bias with Egger's test and Harbord's modification of the Egger test and sensitivity analyses excluding studies in Hardy-Weinberg disequilibrium. Analyses were conducted separately as diagnosis was found to be a modifier. T allele and TT genotype are at a small but statistically significant increased risk of receiving the diagnosis of major psychiatric disorders (SZ, BPD and UDD). No moderating effects were observed for specific diagnosis, sex or ethnic group. The robustness of these findings is underscored by the lack of publication bias. The present meta-analysis on MTHFR A1298C in 3507 patient and 4427 control subjects indicated that carriers of the C allele and CC genotype are small but statistically significant increased risk of being diagnosed with BPD, but not SZ.
OR
Strengths of the meta-analysis
The current report represents the largest published meta-analysis on genetic variations of MTHFR in psychiatric disorders (SZ, Fig. 6 . Results of the random effect meta-analysis of MTHFR A1298C and schizophrenia as tested in genetic model 1. Fig. 7 . Results of the random effect meta-analysis of MTHFR A1298C and bipolar disorder as tested in genetic model 5.
Table 8
Results of the meta-regression analyses of the MTHFR A1298C meta-analysis for the 5 genetic models tested, including diagnosis, year of publication, ethnic group and sex as possible modifiers in separate (one modifier) and combined analyses (multiple modifiers).
Year of publication (coef; p-valu e)
Ethnic group (coef; p-value) Sex (coef; p-value) BPD and UDD) to date. This analysis examined two SNP's associated with three psychiatric disorders, examining both combined major psychiatric disorders as well as individual diagnoses when there was evidence for diagnostic moderation. This is the first meta-analysis examining the association between MTHFR and multiple psychiatric disorders using a cross-disorder designmost meta-analyses available to date have examined the association between MTHFR C677T and diagnoses of a single psychiatric disorder Chen et al., 2009; Cohen-Woods et al., 2010; Gaysina et al., 2008; Shi et al., 2008; Yoshimi et al., 2010) . Meta-analyses conducted by Lewis et al. (6 articles, 2427 (Lewis et al., 2005; Muntjewerff et al., 2006) . Meta-analyses conducted by Gilbody et al. (2007) and Zintzaras (2006) on MTHFR C677T did include several psychiatric disorders. The meta-analysis by Gilbody et al. (2007) included twelve articles on SZ (6125 subjects), four on BPD (1648 subjects), and ten on UDD (11,709 subjects) (Gilbody et al., 2007) . Zintzaras (2006) conducted his meta-analysis at the same time as Gilbody et al. (2007) and included the same articles but differed by including two additional articles (Kempisty et al., 2006; Reif et al., 2005) . Jonsson et al. (2008) conducted a meta-analysis in 2008 examining the association between SZ and both MTHFR C677T and A1298C in a total sample of, respectively 9548 subjects and 6118 subjects (Jonsson et al., 2008) . In addition, the association between BPD and MTHFR C677T and A1298C was examined in a total sample of, respectively 2211 subjects and 792 subjects. Compared with our current report, most of these meta-analyses included fewer studies, a smaller total sample, and MTHFR A1298C was not always consistently examined.
Thus, by examining both the two MTHFR SNP's C677T and A1298C in all five genetic models while including sex, year of publication and ethnic background in the analysis, this meta-analysis provides a good overview of the association between MTHFR gene variants and the psychiatric disorders SZ, BPD and UDD.
Limitations of the meta-analysis
First, although the current study analyzed the largest combined sample so far, the meta-analysis on MTHFR A1298C was performed on a 'relatively' low number of subjects, especially given the minor allele frequency (MAF) of 36% in combination with the small effect sizes reported in the literature. The limited number of studies investigating the MTHFR A1298C polymorphism suggests that type II error cannot be dismissed (Dudbridge and Gusnanto, 2008; O'Donovan et al., 2009) . Second, the use of different designs in the studies included in the meta-analysis may influence the association found between MTHFR and psychiatric disorders. However, all significant gene-disorder associations remained after sensitivity analyses for differences in study design. Third, matching of control subjects was not performed in all studies used in this metaanalysis. However, sensitivity testing indicated that it is unlikely that non-matching of control subjects had substantial influences. Fourth, it is possible that non-uniformity in diagnostic measures may have resulted in heterogeneity between studies and we must acknowledge that the diagnosis of depression in some studies was not based on accepted diagnostic criteria but cut-points in scales. This can create two potential problems: uncertainty about (i) the validity of the diagnosis of depression and (ii) misclassification (for example, if a patient with bipolar disorder was experiencing a depressive episode when s/he completed the rating of the scale). In the first instance, this type of error would lead to a decrease in effect size; in the second it would lead to misclassification bias. Given that the analyses combined the diagnoses of SZ, BPD and UDD, misclassification is not a problem. We may, however, have underestimated the effect of the association. Fifth, the generalizability of the present meta-analysis is limited to the ethnic groups investigated, i.e. White and Asian.
4.4.
Comparison with other meta-analyses on specific diagnoses 4.4.1. Schizophrenia
In line with the current results, the meta-analysis of Yoshimi et al. (2010) supported an association between MTHFR C677T with schizophrenia (Yoshimi et al., 2010) , similar to earlier meta-analyses (Yoshimi: random effects OR = 1.17, 95% CI: 1.07-1.29) Gilbody et al., 2007; Jonsson et al., 2008; Lewis et al., 2005; Muntjewerff et al., 2006; Shi et al., 2008; Zintzaras, 2006) .
Regarding MTHFR A1298C, Zintzaras (2006) concluded in his meta-analysis on 2.565 subjects that this SNP was associated with the diagnosis of schizophrenia, however not in all genetic models examined (fixed effects OR CvA = 1.16, 95% CI: 1.03-1.31; OR AC/CCvAA = 1.19, 95% CI: 1.02-1.40; OR CCvAA = 1.37, 95% CI 1.03-1.82; random effects OR CCvAC/AA = 1.33, 95% CI: 0.94-1.88) (Zintzaras, 2006) . The meta-analysis of Gilbody et al. (2007) on 994 subjects reported only an association in the co-dominant model (fixed effects OR CCvAA = 1.64, 95% CI: 1.05-2.54; genetic model 3), but not in the other model tested (fixed effects OR ACvAA = 1.10, 95% CI 0.84-1.43) (Gilbody et al., 2007) . Jonsson et al. (2008) reported non-significant or only borderline significant results in favor of an association between MTHFR A1298C and SZ in a sample of 6118 subjects (fixed effects OR CvA = 1.09, 95% CI: 1.01-1.18; OR AAvAC/CC = 1.10, 95% CI: 0.99-1.23; OR CCvAA = 1.20, 95% CI 0.99-1.44; OR CCvAC/AA = 1.15, 95% CI: 0.96-1.37; OR ACvAA = 1.08, 95% CI 0.97-1.21) (Jonsson et al., 2008) . Thus, the current sample size in the present meta-analysis (7466 subjects) exceeds earlier studies and indicates that MTHFR A1298C is not significantly associated with SZ in any of the five genetic models.
Bipolar disorder
MTHFR C677T was neither significantly associated with BPD in recent meta-analyses by Cohen-Woods et al. (2010) using a total sample of 2584 subjects nor by Zintzaras (2006) in a sample of 1415 subjects. The meta-analysis by Gilbody et al. (2007) on a total sample of 1648 subjects did find a statistically significant association, which is concordant with the present findings (fixed effects OR TTvCC 1.82, 95% CI: 1.22-2.70; OR TvC = 1.41, 95% CI: 1.19-1.68). Jonsson et al. (2008) Gilbody et al. (2007) (total sample 11,709 subjects: 1280 cases of UDD; 10,429 controls) found evidence of an association between MTHFR C677T and UDD (fixed effects OR TTvCC = 1.36, 95% CI: 1.11-1.67; OR TvC = 1.14, 95% CI: 1.04-1.26; OR CTvCC = 1.10, 95% CI: 0.96-1.25). This was however not supported by the meta-analyses of Zintzaras (2006) with a total sample of 1604 subjects and the meta-analysis of Gaysina et al. (2008) with a total sample of 2566 subjects.
Unipolar depressive disorder
Common genetic vulnerability
As mentioned previously, shared genetic vulnerability for psychiatric disorders has been established by family and twin studies (Cardno et al., 2002; Huang et al., 2010) . A recent report by the International Schizophrenia Consortium furthermore indicated that common genetic variations may account for one third of the total genetic liability of SZ and that this polygenetic risk is shared with BPD (Purcell et al., 2009) . Similarly, a recent GWAS study using a cross-disorder design reported that common genetic variations in the NPAS3 gene are shared between SZ and BPD (Huang et al., 2010) . Similar cross-disorder designs can be applied to recently published GWAS datasets and may be used to replicate the current findings (Baum et al., 2008; Huang et al., 2010; Moskvina et al., 2009; Stefansson et al., 2009 ).
Biological mechanisms underlying common genetic vulnerability in MTHFR
MTHFR is a crucial enzyme involved in one-carbon metabolism (OCM), which is a folate-mediated pathway that is divided into a methylation cycle and a DNA synthesis cycle (Sugden, 2006) . MTHFR catalyses the conversion of 5,10-methylenetetrahydrofolate (5,10-MTHF) to 5-MTHF, the predominant circulating form of folate (Frankenburg, 2007; Krebs et al., 2009; Sugden, 2006) . 5,10-MTHF is involved in DNA synthesis as an essential donor molecule for purines synthesis and a substrate molecule for thymidine synthase, which is a rate limiting step in DNA biosynthesis (Frankenburg, 2007; Krebs et al., 2009; Sugden, 2006) . In the methylation cycle, the methyl group of 5-MTHF is furthermore used for the re-methylation of homocysteine to methionine, and the conversion of methionine to S-adenosylmethionine (SAM), which is a major methyl donor to DNA, proteins, neurotransmitters, hormones and phospholipids (Frankenburg, 2007; Krebs et al., 2009; Sugden, 2006) .
Although the exact role of OCM in neurodevelopment has not been well characterized, evidence from both experimental animal and human studies has shown that components of OCM (del Rio Garcia et al., 2009; Dror and Allen, 2008; Zeisel, 2009 ) influences brain development, brain maturation and function. Thus, given the crucial role of MTHFR in OCM, the biological mechanism underlying the common genetic vulnerability of MTHFR may result in (i) aberrant methylation (Zeisel, 2009) , (ii) aberrant DNA synthesis (Greenblatt et al., 1994) , and (iii) increased turnover of neurotransmitters (Bottiglieri et al., 2000; Greenblatt et al., 1994) . The absence of clear evidence for major genetic effects, despite (high) estimates of heritability for major psychiatric disorders, together with evidence of 'causal' environmental exposures resulting in changes in gene expression is consistent with the concept that the biologic underpinnings of psychiatric disorders are epigenetic in form rather than DNA sequence-based (Dror and Allen, 2008; Zeisel, 2009) . DNA methylation is a critical epigenetic modification of the genome that controls many biologic processes, including embryonic development, X-chromosome inactivation, imprinting, and gene expression (Bredy et al., 2010; Stahl, 2010) . Although methylation patterns are established during early life, they are not fixed, and gradual hypomethylation of the genome is reported to occur with age, together with aberrant hypermethylation of gene promoter regions (Lahiri et al., 2009 ). Thus, the correct establishment of DNA methylation patterns is important not only during early life but also for long-term health benefits, including psychiatric and neurologic disease susceptibility (Lahiri et al., 2009) .
To conclude, the results of this meta-analysis are consistent with the hypothesis that SZ, BPD and UDD share a common genetic vulnerability linked to the common MTHFR C677T polymorphism. Given the link between genetic variations of MTHFR and differential methylation potentials, these results support the epigenetic hypothesis of major psychiatric disorders.
